Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) used to manage chronic hepatitis B and HIV infection.
Lamivudine belongs to a class of medicines called nucleoside reverse-transcriptase inhibitors. It helps stop the replication of certain viruses by interfering with their genetic material. In Hong Kong, lamivudine is found in several prescription products, including Epivir, Triumeq, and Viropil.
Lamivudine is available in a range of formulations. Epivir is a standalone tablet that contains only lamivudine, usually taken once daily. Triumeq combines lamivudine with two other antivirals in a single tablet, offering a convenient option for people on combination therapy. Viropil is a fixed-dose tablet that pairs lamivudine with another drug to treat hepatitis B. All three products are approved for use in Hong Kong and are supplied in standard tablet strengths. Generic versions of lamivudine also exist, providing the same active ingredient at a lower cost.
People who need long-term viral suppression often use lamivudine as part of a broader regimen. The medication is prescribed for adults and adolescents, but the exact age groups are detailed on each product’s label. While lamivudine is officially approved for the conditions above, doctors may occasionally consider it for related viral infections based on individual assessment.
Lamivudine mimics a natural building block of viral DNA. When the virus tries to copy its genetic code, lamivudine is incorporated instead, causing the chain to stop growing. This halts the production of new viruses, allowing the body’s immune defences to keep the infection in check. Effects are usually seen within a few weeks of starting therapy, but full viral suppression can take several months.
Most people experience only mild reactions. These may include headache, fatigue, nausea, or a temporary feeling of dizziness. Skin rashes or mild stomach discomfort are also reported but typically resolve without medical intervention.
Although rare, some individuals develop severe allergic reactions. Warning signs include swelling of the face or throat, difficulty breathing, or a sudden rash that spreads quickly. If any of these occur, seek emergency care right away.
Lamivudine should be used with care in people with known liver disease, severe kidney impairment, or a history of allergic reactions to nucleoside analogues. Pregnant or breastfeeding individuals must discuss potential risks with their clinician, as the medication crosses the placenta and enters breast milk.
Lamivudine may interact with other antiviral drugs, certain antibiotics, and medications that affect kidney function. Alcohol can increase liver stress, so moderation is advised. Driving or operating heavy machinery is generally safe, but any severe dizziness should be reported to a health professional. For a complete list of possible interactions, see the information provided with each specific product.
Store tablets at room temperature, away from direct sunlight and moisture. Keep them out of reach of children. Treatment length varies: some people use lamivudine for a short course, while others continue indefinitely under medical supervision. Always follow the instructions that come with your particular medication. For detailed usage, dosing, and administration, refer to the specific medication’s information.
This article offers general educational information about lamivudine as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing lamivudine may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.
